A pooled analysis of 95 AF studies reported that only 56% (95% CI, 53–59%) of the measured INRs were in the therapeutic range, and the patients were 61% (95% CI, 59–62%) of the time in TTR (Mearns et al., 2014). This evidence concerns the gene TTR and atrial fibrillation.